Acute Myeloid Leukemia

No higher risk of acute leukaemia in close relatives

(Medical Xpress) -- Parents, siblings and children of patients with the most common form of acute leukemia do not run a higher risk of developing the disease as was once believed, according to a new study from the Swedish ...

Dec 15, 2011
popularity0 comments 0

Protein pathways provide clues in leukemia research

Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

May 31, 2012
popularity0 comments 0

Better prognosis for early blast clearance in leukemia

(HealthDay)—Patients with acute myeloid leukemia whose peripheral blood blasts clear in six days or less after chemotherapy have significantly better survival than patients whose peripheral blasts clear later, according ...

Oct 24, 2012
popularity0 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Study examines the rise of plaque in arteries

The accumulation of cholesterol plaques in artery walls can lead to atherosclerosis, or the hardening of arteries that contributes to heart attacks and strokes. In a new study, Yale researchers investigate how plaque cells ...

Research could help fine-tune cancer treatment

Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Aggression neurons identified

High activity in a relatively poorly studied group of brain cells can be linked to aggressive behaviour in mice, a new study from Karolinska Institutet in Sweden shows. Using optogenetic techniques, the researchers were able ...